



(51) International Patent Classification:

A61K 9/16 (2006.01) *A61P 1/16* (2006.01)
A61K 9/48 (2006.01) *A61P 13/10* (2006.01)
A61P 37/06 (2006.01) *A61P 13/12* (2006.01)
A61K 31/4439 (2006.01) *A61K 9/20* (2006.01)
C07D 401/12 (2006.01)

(21) International Application Number:

PCT/EP2021/060764

(22) International Filing Date:

24 April 2021 (24.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20171441.7 24 April 2020 (24.04.2020) EP
 20211697.6 03 December 2020 (03.12.2020) EP

(71) Applicants: **DR. FALK PHARMA GMBH** [DE/DE];
 Leinenweberstr. 5, 79108 Freiburg (DE). **ZEDIRA GMBH**
 [DE/DE]; Roesslerstrasse 83, 64293 Darmstadt (DE).

(72) Inventors: **GREINWALD, Roland**; Jakob-Otter-Straße 2,
 79341 Kenzingen (DE). **HILS, Martin**; Ingelheimerstr. 9b,
 64295 Darmstadt (DE). **MOHR, Wolfgang**; Komturstasse
 39a, 79106 Freiburg (DE). **PASTERNAK, Ralf**; Jahnstr.
 6, 64347 Griesheim (DE). **TEWES, Bernhard**; Reutack-
 ering 23, 79279 Vörsstetten (DE). **WILHELM, Rudolf**;
 Feuerkirschenweg 2A, 76476 Bischweier (DE).


(74) Agent: **ARTH, Hans-Lothar**; ABK Patent Attorneys Jas-
 minweg 9, 14052 Berlin (DE).

(81) Designated States (*unless otherwise indicated, for every
 kind of national protection available*): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) Title: SYSTEMIC FORMULATION OF A PYRIDINONE DERIVATE FOR TG2-RELATED DISEASES

Figure 9

Reduction of fibrotic area vs. Cmax



(57) **Abstract:** The present invention relates to a formulation in particular an oral formulation for the prophylaxis and treatment of TG2-related disorders like fibrosis in particular diabetic nephropathy and/or diabetic associated non-alcoholic steatohepatitis (NASH) and/or non-alcoholic steatohepatitis, and its use in the prophylaxis and/or treatment of fibrosis in particular nephropathy, NASH, idiopathic pulmonary fibrosis, and cystic fibrosis. Further, the present application relates also to the use of (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate as hepatoprotectant, i.e. as hepatoprotective agent. In addition the present invention relates to a pharmaceutical composition comprising (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate for use as hepatoprotective agent and for use in the protection of the liver against liver toxicity, the improvement of liver function, and/or in the prophylaxis or treatment of a liver disease or liver disorder.

[Continued on next page]

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))